714 related articles for article (PubMed ID: 34207510)
1. Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms.
Montero P; Milara J; Roger I; Cortijo J
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207510
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease.
Huo R; Guo Q; Hu J; Li N; Gao R; Mi L; Zhang Z; Liu H; Guo Z; Zhao H; Zhang L; Xu K
Drug Des Devel Ther; 2022; 16():991-998. PubMed ID: 35400994
[TBL] [Abstract][Full Text] [Related]
3. The Role of JAK/STAT Molecular Pathway in Vascular Remodeling Associated with Pulmonary Hypertension.
Roger I; Milara J; Montero P; Cortijo J
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34067108
[TBL] [Abstract][Full Text] [Related]
4. The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease.
Talotta R
Immunotherapy; 2021 Feb; 13(3):241-256. PubMed ID: 33410346
[TBL] [Abstract][Full Text] [Related]
5. The Role of JAK/STAT Pathway in Fibrotic Diseases: Molecular and Cellular Mechanisms.
Liu J; Wang F; Luo F
Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671504
[TBL] [Abstract][Full Text] [Related]
6. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
7. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
8. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
[TBL] [Abstract][Full Text] [Related]
9. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
[TBL] [Abstract][Full Text] [Related]
10. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
[TBL] [Abstract][Full Text] [Related]
11. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
Coskun M; Salem M; Pedersen J; Nielsen OH
Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
Migita K; Izumi Y; Torigoshi T; Satomura K; Izumi M; Nishino Y; Jiuchi Y; Nakamura M; Kozuru H; Nonaka F; Eguchi K; Kawakami A; Motokawa S
Clin Exp Immunol; 2013 Dec; 174(3):356-63. PubMed ID: 23968543
[TBL] [Abstract][Full Text] [Related]
13. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors.
Welsch K; Holstein J; Laurence A; Ghoreschi K
Eur J Immunol; 2017 Jul; 47(7):1096-1107. PubMed ID: 28555727
[TBL] [Abstract][Full Text] [Related]
14. Mining for JAK-STAT mutations in cancer.
Constantinescu SN; Girardot M; Pecquet C
Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
[TBL] [Abstract][Full Text] [Related]
15. [Research Advances of JAK/STAT Signaling Pathway in Lung Cancer].
Yang X; Tang Z; Zhang P; Zhang L
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):45-51. PubMed ID: 30674393
[TBL] [Abstract][Full Text] [Related]
16. The JAK/STAT signaling pathway: from bench to clinic.
Hu X; Li J; Fu M; Zhao X; Wang W
Signal Transduct Target Ther; 2021 Nov; 6(1):402. PubMed ID: 34824210
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatment with resveratrol alleviates adjuvant arthritis-interstitial lung disease in rats via modulation of JAK/STAT/RANKL signaling pathway.
Yang G; Lyu L; Wang X; Bao L; Lyu B; Lin Z
Pulm Pharmacol Ther; 2019 Jun; 56():69-74. PubMed ID: 30930172
[TBL] [Abstract][Full Text] [Related]
18. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of the Jak/STAT pathway.
Aittomäki S; Pesu M
Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):18-23. PubMed ID: 24164900
[TBL] [Abstract][Full Text] [Related]
20. Effect of Baricitinib on the epithelial-mesenchymal transition of alveolar epithelial cells induced by IL-6.
Liu Y; Hu M; Fan G; Xing N; Zhang R
Int Immunopharmacol; 2022 Sep; 110():109044. PubMed ID: 35850052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
